Bottom line
BIB vs FBT: the short answer
BIB (ProShares Ultra Nasdaq Biotechnology) and FBT (First Trust NYSE Arca Biotechnology Index Fund) are both etfs.
But BIB is far broader, holding 267 positions to 32 for FBT, so beyond the top names it adds exposure FBT doesn't have.
FBT is cheaper at 0.55% vs 0.95% — a difference of $40 a year per $10,000 invested.
Over five years, FBT returned +4.3% a year vs −1.0% for BIB.
Updated Nov 19, 2026
BIB vs FBT side by side
| BIB | FBT | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | ProShares | First Trust |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.95% | 0.55% |
| Annual cost per $10k | $95 | $55 |
| 10-yr cost on $10k (prospectus) | $1,401 | — |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +59.3% | +24.1% |
| 5-yr return (annualized) | −1.0% | +4.3% |
| 10-yr return (annualized) | +1.4% | +6.3% |
| Best quarter | +56.2% | +27.8% |
| Worst quarter | −42.7% | −22.5% |
| Net assets (fund) | $73.7M | $2.8B |
| Number of holdings | 267 | 32 |
| Portfolio turnover | 29% | 37% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BIB | FBT | Difference |
|---|---|---|---|
| 2025 | +59.3% | +24.1% | +35.3% |
| 2024 | −10.0% | +5.8% | −15.8% |
| 2023 | −1.3% | +2.3% | −3.5% |
| 2022 | −28.6% | −4.6% | −24.0% |
| 2021 | −5.9% | −3.6% | −2.3% |
| 2020 | +39.7% | +12.9% | +26.8% |
| 2019 | +45.5% | +19.8% | +25.7% |
| 2018 | −24.4% | −0.2% | −24.2% |
| 2017 | +40.8% | +37.0% | +3.8% |
| 2016 | −44.2% | −19.6% | −24.6% |
Source: Fund prospectus bar charts
Holdings overlap
8 of BIB's top 25 holdings also appear in FBT's top 25.
| Holding | BIB | FBT |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 4.65% | 3.07% |
| Amgen, Inc. | 4.48% | 2.78% |
| Alnylam Pharmaceuticals, Inc. | 2.01% | 2.52% |
| Biogen, Inc. | 1.44% | 3.37% |
| Illumina, Inc. | 1.25% | 3.92% |
| United Therapeutics Corp. | 1.22% | 2.56% |
| Argenx SE | 1.19% | 3.13% |
| Incyte Corp. | 0.97% | 3.18% |
Source: SEC Form N-PORT
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FBT top 10
- Corcept Therapeutics Inc — 5.60%
- Neogenomics Inc — 5.12%
- Veracyte Inc — 5.10%
- Bruker Corp — 4.32%
- Alkermes Plc — 4.24%
- Illumina Inc — 3.92%
- Krystal Biotech Inc — 3.87%
- Natera Inc — 3.79%
- Axsome Therapeutics Inc — 3.71%
- Neurocrine Biosciences Inc — 3.53%
FAQ
What is the difference between BIB and FBT?
Which is cheaper, BIB or FBT?
Should I own both BIB and FBT?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.